ALPMY News and Press, Astellas Pharma Inc. ADR From 10/30/23

FMC Corporation (FMC) is expected to report $0.45 for Q3 2023 NCS Multistage Holdings Inc. (NCSM) is expected to report $2.59 for Q3 2023 Third Century Bancorp (TDCB) is expected to report for Q3 2023 ZoomInfo Technologies Inc. (ZI) is expected to report $0.15 for Q3 2023 Matson I...

Astellas Pharma Inc. ADR (ALPMY) is expected to report for Q2 2024

2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...

2023-10-23 14:25:26 ET More on Seattle Genetics Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Seagen ticks higher as EU approves $43B sale to Pfizer Pfizer likely turned over all documents to FTC for Seagen acquistion - r...

Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer PR Newswire – Risk of death was re...

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023 PR Newswire Data include three late-breaking abstracts, underscoring Astellas' efforts to potentially redefine expectations for patients across its oncology portfolio TOKYO , Oc...

2023-10-13 09:38:00 ET More on Astellas Pharma ADR Astellas: Earnings Power, Asset Factors Attractive, Reiterate Hold On Valuation Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript Merck succeeds in Phase 3 trial for bladder cancer therapy Apellis...

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant) PR Newswire Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 worldwide experience VMS, with rat...

Astellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, Japan PR Newswire - Open Innovation Hub Named SakuLab TM -Tsukuba will open at the Astellas Tsukuba Research Center - TOKYO and ...

2023-10-05 07:30:43 ET More on Merck Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck: A Blue-Chip Dividend Stock Worth Buying US government to stop distributing Merck's CO...